Keyphrases
Curcumin
88%
Cisplatin
56%
Doxorubicin
50%
Nanocurcumin
49%
α-mangostin
45%
MRNA Expression
42%
Drug Transporters
38%
Indonesia
37%
Leukemia Patients
35%
Indonesian
33%
Clinical Trials
31%
Rat Model
30%
MCF-7
28%
Breast Cancer Cells
28%
Hepatic Stellate Cells
27%
In Vitro Study
27%
Meta-analysis
27%
Triple-negative Breast Cancer Cells
26%
Primaquine
25%
Cell Viability
25%
Transmembrane
25%
Androgens
25%
Prostate
25%
Antioxidant System
24%
Sprague-Dawley Rats
23%
Sorafenib
21%
Systematic Meta-analysis
20%
COVID-19
20%
Insulin Resistance
20%
Human Breast Cancer Stem Cells
20%
Endoxifen
20%
Acute Myeloid Leukemia
20%
Evidence-based Case Report
20%
Kidney
20%
Chronic Myeloid Leukemia
19%
Multidrug Resistance Protein 1 (MDR1)
19%
Epithelial-mesenchymal Transition
18%
Oxidative Stress
18%
Acute Lymphoblastic Leukemia
17%
High-fat Diet
17%
Plasma Concentration
17%
Ovarian Cancer
17%
Andrographolide
17%
Oxidative Stress Markers
16%
Cisplatin-induced
16%
Anticancer Activity
16%
Pharmacokinetic Profile
16%
Genotype
16%
Universitas Indonesia
16%
P-glycoprotein (P-gp)
16%
Pharmacology, Toxicology and Pharmaceutical Science
Curcumin
100%
Cisplatin
69%
Breast Cancer
68%
Doxorubicin
57%
Messenger RNA
49%
Malignant Neoplasm
37%
Clinical Trial
32%
Antioxidant
32%
Effusion
28%
Sorafenib
26%
Tamoxifen
26%
Primaquine
25%
Triple Negative Breast Cancer
25%
Moringa oleifera
25%
Liver Fibrosis
24%
Sprague Dawley Rat
23%
Ovary Cancer
23%
Cell Viability
22%
Rat Model
20%
Insulin Resistance
20%
Nephrotoxicity
19%
Endoxifen
19%
Andrographolide
18%
P-Glycoprotein
18%
ABCG2
18%
Survivin
18%
Acute Lymphoblastic Leukemia
17%
Pharmacokinetics
17%
Mouse Model
17%
Diseases
16%
Cardiotoxicity
16%
Non Insulin Dependent Diabetes Mellitus
16%
Cross-Sectional Study
16%
Imatinib
16%
Androgen
15%
Chronic Myeloid Leukemia
15%
Biological Marker
15%
Ritonavir
15%
Radiosensitizing Agent
15%
Quercetin
15%
Clopidogrel
15%
Acute Myeloid Leukemia
15%
Blood Toxicity
15%
Acetaldehyde
15%
Cancer Growth Factor
14%
Nanoparticle
14%
Transcription Factor Nrf2
14%
Adverse Event
14%
Liver Cell Carcinoma
14%
Mercaptopurine
13%